- Dr. Marvin Hausman joins Exousia Pro (MAJI, Financial) as a consultant to host a new weekly web series "Ask Dr. Hausman."
- The clinical-stage biotech company focuses on exosome therapies for cancer and other diseases.
- Dr. Hausman's extensive network in the biotech sector expected to drive new growth opportunities for Exousia Pro.
Exousia Pro, trading under the ticker MAJI on OTCPINK, has announced the engagement of Dr. Marvin Hausman as a consultant. The company is set to launch a new weekly web series titled "Ask Dr. Hausman," where shareholders can submit questions to be answered by the industry expert. The series will also provide updates on ongoing studies, FDA submissions, and future Investigational New Drug (IND) trials. This initiative is aimed at enhancing transparency and shareholder engagement.
Dr. Hausman, a key figure in the creation of Exousia AI and the Glioblastoma study collaboration with the University of Central Florida (UCF), will leverage his vast network of scientific and financial professionals to advance Exousia Pro's mission. The company's President, Matt Dwyer, has expressed confidence that Dr. Hausman's involvement will unlock new opportunities for the advancement of their plant-based exosome therapies.
Exousia Pro is a clinical-stage biotechnology firm that focuses on developing exosome-based therapies, primarily targeting cancer treatment. Utilizing proprietary technology, the company creates plant-based exosomes for a range of applications, including oncology, dermatology, and dentistry. For more information, visit their website at www.exousiapro.com.
